Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Regulatory News (ORPH)

  • There is currently no data for ORPH

Offer Wholly Unconditional

17 Jan 2020 07:00

RNS Number : 0961A
Open Orphan PLC
17 January 2020
Β 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF ANY SUCH JURISDICTION

Β 

17 January 2020

Recommended All Equity Offer

for

HVIVO PLC ("HVIVO")

to merge with

OPEN ORPHAN PLC ("OPEN ORPHAN")

Β 

Β Offer Wholly Unconditional

Introduction

On 9 December 2019, the boards of Open Orphan and hVIVO announced that they had reached agreement on the terms of a recommended all-equity offer for the entire issued and to be issued share capital of hVIVO (the "Offer"). Under the terms of the Offer, hVIVO Shareholders will be entitled to receive 2.47 New Open Orphan Shares for every one hVIVO Share. The Offer represents a value of approximately 15.56 pence per hVIVO Share and a premium of 33.8 per cent. based upon the hVIVO Closing Price on 6 December 2019, being the last practicable date prior to announcement of the Offer, valuing hVIVO at approximately Β£12.96 million.

On 31 December 2019, Open Orphan announced that the Offer had been declared unconditional as to acceptances and on 14 January 2020 announced that it had received acceptances in respect of 77,348,100 hVIVO Shares, representing approximately 92.5 per cent. of the issued ordinary share capital of hVIVO.

Offer Wholly Unconditional

Open Orphan announces that it has decided, in accordance with the Offer Document, to waive the outstanding conditions under the Offer. Accordingly, there are no further conditions to be satisfied and the Offer is now unconditional in all respects.

Admission of the Enlarged Share Capital

Application has been made for the admission of the Consideration Shares and the Existing Ordinary Shares, being 445,622,374 Ordinary Shares to trading on AIM and Euronext Growth, which is expected to become effective and dealings commence at 8.00 a.m. on 20 January 2020.

Compulsory acquisition

Open Orphan intends to shortly exercise its rights pursuant to the provisions of sections 974-991 of the Companies Act to compulsorily acquire the remaining hVIVO Shares. The compulsory acquisition will be settled on the same terms as the Offer and hVIVO Shareholders will be entitled to receive 2.47 Open Orphan Shares for every 1 hVIVO Share.

In exercising such rights in respect of hVIVO Shares held by hVIVO Shareholders in, or with a registered address in, a Restricted Jurisdiction, Open Orphan may elect to arrange for such hVIVO Shares to be sold on behalf of the relevant hVIVO Shareholder and the proceeds (less the costs and expenses of such sale) remitted to such hVIVO Shareholder.

Enquiries:

Β 

Open Orphan plc

Cathal Friel, Chief Executive Officer

Β 

+353 (0)1 644 0007

Arden Partners plc (Nominated Adviser and Joint Broker)

John Llewellyn-Lloyd / Ben Cryer

Β 

+44 (0)20 7614 5900

JE Davy (Euronext Adviser and Joint Broker)

Anthony Farrell

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Β 
END
Β 
Β 
OUPUNUARRRUAAUR
Date   Source Headline
10th May 20197:00 amRNSPreliminary Final Results
1st May 201911:00 amRNSChanges to interests of a significant shareholder
1st May 201911:00 amRNSIntegumen Debt Conversion
8th Apr 20197:00 amRNSFinancing Update
26th Mar 20197:00 amRNSChange of Adviser
21st Jan 20194:40 pmRNSSecond Price Monitoring Extn
21st Jan 20194:35 pmRNSPrice Monitoring Extension
18th Jan 20197:00 amRNSPartnership Announcement
24th Dec 201812:36 pmRNSPrice Monitoring Extension
21st Dec 20184:29 pmRNSDirector/PDMR Shareholding
20th Dec 20185:04 pmRNSHolding(s) in Company
11th Dec 20187:00 amRNSStrategic Collaboration Agreement and Financing
8th Nov 201810:40 amRNSTrading Update and Change of Adviser
5th Oct 20183:36 pmRNSHolding(s) in Company
25th Sep 20187:00 amRNSHalf-year Report
17th Sep 20187:00 amRNSFirst laboratory-grown human-skin test service
30th Jul 201811:27 amRNSHolding(s) in Company
26th Jul 20185:01 pmRNSHolding(s) in Company
26th Jul 20185:00 pmRNSHolding(s) in Company
26th Jul 20183:40 pmRNSHolding(s) in Company
24th Jul 20188:00 amRNSEnterprise Securities Market Notice
24th Jul 20188:00 amRNSEnterprise Securities Market Notice
20th Jul 20183:22 pmRNSResult of General Meeting
4th Jul 20187:00 amRNSPlacing & Subscription to raise up to £0.65m
28th Jun 201811:47 amRNSResult of AGM
6th Jun 20184:55 pmRNSNotice of AGM & Posting of Annual Report&Accounts
17th May 20187:00 amRNSFinal Results
23rd Apr 20187:00 amRNSNotice of Results
21st Mar 20187:00 amRNSDirectorate Change
15th Feb 20187:00 amRNSTrading Statement
25th Jan 20187:00 amRNSChange of Adviser
23rd Jan 20187:00 amRNSAcquisition of Minority Interest
14th Sep 20175:19 pmRNSGrant of Stock Options
12th Sep 20177:00 amRNSHalf-year Report
25th Jul 20177:00 amRNSSenior Management Appointment
20th Jul 20177:00 amRNSHalf year end update
26th Apr 20176:01 pmRNSResult of AGM
25th Apr 20173:13 pmRNSProposed amendment to AGM resolution
5th Apr 20177:00 amRNSIntegumen IPO
4th Apr 20177:00 amRNSEnterprise Securities Market Notice
31st Mar 201711:26 amRNSAnnual Financial Report & Notice of AGM
29th Mar 20171:57 pmRNSIssue of Equity
22nd Mar 20177:00 amRNSFinal Results
3rd Mar 20177:00 amRNSYear End Update
18th Nov 20167:00 amRNSCompletion of Sale
10th Nov 20165:51 pmRNSREPLACEMENT - Contract win
8th Nov 20167:00 amRNSContract win
2nd Nov 20167:03 amRNSDirector/PDMR Shareholding
27th Oct 20167:00 amRNSSale of Innovenn UK Limited and Result of GM
4th Oct 20167:00 amRNSSale of Innovenn & Notice of General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.